Overview

Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
To assess the clinically active dose range of study medication in the treatment of patients with rheumatoid arthritis.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Diclofenac
Etoricoxib